Lakefront Biotherapeutics NV (GLPG)
NGM · Healthcare · Biotechnology
Closing price as of 2026-07-02 · Source: TEK2day Finance
Key Metrics
About Lakefront Biotherapeutics NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Quarterly Financials (EUR)
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 65.3M | 71.2M | 900.8M | 6.5M |
| Gross Profit | 60.6M | 60.3M | 900.4M | 1.7M |
| Operating Income | (57.0M) | (41.7M) | 758.8M | (63.7M) |
| Net Income | (105.7M) | (202.1M) | 782.1M | 14.5M |
| Diluted EPS | EUR 0.22 |
Annual Financials (EUR)
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 241.2M | 239.7M | 275.6M | 1.1B |
| Gross Profit | 241.2M | 239.7M | 240.8M | 1.1B |
| Operating Income | (131.1M) | (88.3M) | (188.3M) | 501.4M |
| Net Income | (218.0M) | 211.7M | 74.1M | 320.9M |
| Diluted EPS | (EUR 3.32) | EUR 3.21 | EUR 1.12 | EUR 4.87 |